Options
Patent
Title
Chemisch modifizierte Peptidanaloga
Other Title
Peptide derivative, for the treatment of diabetes and Alzheimer's disease, is a chemically modified islet amyloid polypeptide analog.
Abstract
Die vorliegende Erfindung betrifft verbesserte Mittel und Verfahren zur Behandlung von Diabetes und Alzheimer-Krankheit unter Verwendung von IAPP-Peptidderivaten.
;
DE1004051014 A UPAB: 20060809 NOVELTY - The islet amyloid polypeptide (IAPP) analog, with the ability to bond with natural IAPP receptors, has a maximum of 38 amino acids of which 37 residues follow the sequence of a natural IAPP and at least 19-37 have amino acids in a natural sequence. DETAILED DESCRIPTION - The islet amyloid polypeptide (IAPP) analog, with the ability to bond with natural IAPP receptors, has a maximum of 38 amino acids of which 37 residues follow the sequence of a natural IAPP and at least 19-37 have amino acids in a natural sequence. At least one of the amide bonds is N-methylated. Optionally natural lysine in position 1 can be replaced by ornithine, and/or cysteines at positions 2 and 7 can be replaced by diaminopropionic acid and asparagine acid, respectively, or vice versa. The peptide analogs have the sequence SEQ ID Nos.1-5 as defined in the specification. ACTIVITY - Antidiabetic; Neuroprotective; Nootropic. No biological data given. MECHANISM OF ACTION - None given. USE - The peptide derivative is for the treatment of diabetes and Alzheimer's disease. ADVANTAGE - The peptide derivative is in an isolated partially or wholly cleaned form, for an improved prophylaxis, therapy and diagnosis of diabetes and Alzheimer's disease.
Inventor(s)
Kapurniotu, A.
Patent Number
102004051014
Publication Date
2006
Language
German